ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022

Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101).

Hani Babiker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.